Neoviridogrisein I
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-02120 |
CAS | 66002-39-9 |
Molecular Weight | 877.03 |
Molecular Formula | C45H64N8O10 |
Online Inquiry
Description
It is produced by the strain of Str. griseoviridus P8648. Neoviridogrisein I has been used to resist gram-positive bacteria and mycoplasma.
Specification
Synonyms | (3-D-proline)-[6-(L-2-amino-butyric acid)]-etamycin-A |
IUPAC Name | N-[(3R,6S,7R,10S,13S,16S,22R)-13-ethyl-7,11,17,20-tetramethyl-16-(3-methylbutan-2-yl)-3-(2-methylpropyl)-2,5,9,12,15,18,21-heptaoxo-10-phenyl-8-oxa-1,4,11,14,17,20-hexazabicyclo[20.3.0]pentacosan-6-yl]-3-hydroxypyridine-2-carboxamide |
Canonical SMILES | CCC1C(=O)N(C(C(=O)OC(C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)N1)C(C)C(C)C)C)C)CC(C)C)NC(=O)C3=C(C=CC=N3)O)C)C4=CC=CC=C4)C |
InChI | InChI=1S/C45H64N8O10/c1-11-30-42(59)52(10)38(29-17-13-12-14-18-29)45(62)63-28(7)35(49-40(57)36-33(54)20-15-21-46-36)39(56)48-31(23-25(2)3)43(60)53-22-16-19-32(53)44(61)50(8)24-34(55)51(9)37(41(58)47-30)27(6)26(4)5/h12-15,17-18,20-21,25-28,30-32,35,37-38,54H,11,16,19,22-24H2,1-10H3,(H,47,58)(H,48,56)(H,49,57)/t27?,28-,30+,31-,32-,35+,37+,38+/m1/s1 |
InChI Key | NPHUKIOGHFYZCW-KTWIDACSSA-N |
Properties
Antibiotic Activity Spectrum | Gram-positive bacteria; mycoplasma |
Melting Point | 143°C |
Reference Reading
1. Discovery of Nosiheptide, Griseoviridin, and Etamycin as Potent Anti-Mycobacterial Agents against Mycobacterium avium Complex
Kanji Hosoda, Nobuhiro Koyama, Akihiko Kanamoto, Hiroshi Tomoda Molecules. 2019 Apr 16;24(8):1495. doi: 10.3390/molecules24081495.
Mycobacterium avium complex (MAC) is a serious disease mainly caused by M. avium and M. intracellulare. Although the incidence of MAC infection is increasing worldwide, only a few agents are clinically used, and their therapeutic effects are limited. Therefore, new anti-MAC agents are needed. Approximately 6600 microbial samples were screened for new anti-mycobacterial agents that inhibit the growth of both M. avium and M. intracellulare, and two culture broths derived from marine actinomycete strains OPMA1245 and OPMA1730 had strong activity. Nosiheptide (1) was isolated from the culture broth of OPMA1245, and griseoviridin (2) and etamycin (viridogrisein) (3) were isolated from the culture broth of OPMA1730. They had potent anti-mycobacterial activity against M. avium and M. intracellulare with minimum inhibitory concentrations (MICs) between 0.024 and 1.56 μg/mL. In addition, a combination of 2 and 3 markedly enhanced the anti-mycobacterial activity against both M. avium and M. intracellulare. Furthermore, a combination 2 and 3 had a therapeutic effect comparable to that of ethambutol in a silkworm infection assay with M. smegmatis.
2. The Diversity, Metabolomics Profiling, and the Pharmacological Potential of Actinomycetes Isolated from the Estremadura Spur Pockmarks (Portugal)
António Pinto-Almeida, Anelize Bauermeister, Luca Luppino, Inês R Grilo, Juliana Oliveira, Joana R Sousa, Daniel Petras, Clara F Rodrigues, Alejandra Prieto-Davó, Deniz Tasdemir, Rita G Sobral, Susana P Gaudêncio Mar Drugs. 2021 Dec 23;20(1):21. doi: 10.3390/md20010021.
The Estremadura Spur pockmarks are a unique and unexplored ecosystem located in the North Atlantic, off the coast of Portugal. A total of 85 marine-derived actinomycetes were isolated and cultured from sediments collected from this ecosystem at a depth of 200 to 350 m. Nine genera, Streptomyces, Micromonospora, Saccharopolyspora, Actinomadura, Actinopolymorpha, Nocardiopsis, Saccharomonospora, Stackebrandtia, and Verrucosispora were identified by 16S rRNA gene sequencing analyses, from which the first two were the most predominant. Non-targeted LC-MS/MS, in combination with molecular networking, revealed high metabolite diversity, including several known metabolites, such as surugamide, antimycin, etamycin, physostigmine, desferrioxamine, ikarugamycin, piericidine, and rakicidin derivatives, as well as numerous unidentified metabolites. Taxonomy was the strongest parameter influencing the metabolite production, highlighting the different biosynthetic potentials of phylogenetically related actinomycetes; the majority of the chemical classes can be used as chemotaxonomic markers, as the metabolite distribution was mostly genera-specific. The EtOAc extracts of the actinomycete isolates demonstrated antimicrobial and antioxidant activity. Altogether, this study demonstrates that the Estremadura Spur is a source of actinomycetes with potential applications for biotechnology. It highlights the importance of investigating actinomycetes from unique ecosystems, such as pockmarks, as the metabolite production reflects their adaptation to this habitat.
3. Etamycin as a Novel Mycobacterium abscessus Inhibitor
Bui Thi Bich Hanh, Tae Ho Kim, June-Woo Park, Da-Gyum Lee, Jae-Sung Kim, Young Eun Du, Chul-Su Yang, Dong-Chan Oh, Jichan Jang Int J Mol Sci. 2020 Sep 21;21(18):6908. doi: 10.3390/ijms21186908.
The increase in drug-resistant Mycobacterium abscessus, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against M. abscessus. We found that etamycin significantly inhibited the growth of M. abscessus wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of M. abscessus that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (Danio rerio) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating M. abscessus infections. Thus, we concluded that etamycin is a potential anti-M. abscessus candidate for further development as a clinical drug candidate.
Recommended Products
BBF-03488 | Streptozotocin | Inquiry |
BBF-03428 | Tubermycin B | Inquiry |
BBF-05818 | Docosahexaenoic acid | Inquiry |
BBF-05877 | Coenzyme Q10 | Inquiry |
BBF-02582 | Polyporenic acid C | Inquiry |
BBF-00664 | Alternariol | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳